Figure 6

Ex vivo drug response and outcome is not affected by STAP1 overexpression. (a,b) The association between high expression levels of STAP1, and cumulative incidence of relapse (CIR) and event-free-survival (EFS) was examined. Patients were stratified according to treatment protocol (i.e. COALL-97 or -03, or the DCOG protocols ALL8, ALL9, or ALL10). CIR was estimated using a competing risk model with relapse and non-response as event and death as competing event. The Gray’s test was applied. Relapse, non-response, secondary malignancies and death were considered as events for EFS. EFS rates were determined using Cox regression, and compared using the Wald test. (c–h) Leukemic cells were exposed for four days to an increasing concentration range of prednisolone (µg/ml), vincristine (µg/ml), L-asparaginase (IU/ml), daunorubicin (µg/ml), 6-mercaptopurine (µg/ml), and 6-thioguanine (µg/ml). Cell survival was measured using an MTT assay. To compare LC50-values, the Mann-Whitney U test was applied. BO = non-BCR-ABL1-like B-other BCP-ALL cases. BAL = BCR-ABL1-like BCP-ALL cases.’